PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington’s disease is a research paper published in Molecular Therapy — Methods & Clinical Development (2022). On theSindex it has a DataRank of 0.651. It has been cited 17 times, with 15 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.434
From this paper's citation signal
Citation Network Contribution
0.218
From 11 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 15 citers.
NINDS
Grant: NS105709
NINDS
Grant: NS119471
NINDS NIH HHS
Grant: R01 NS119471
NINDS NIH HHS
Grant: R01 NS105709
National Institutes of Health
Grant: 5R01NS105709-02
Genetic foundation for complete mutant allele-specific CRISPR in neurodegenerative diseases
National Institutes of Health
Grant: 5R01NS119471-02
Therapeutic potential of base editing strategies to convert CAG to CAA in Huntington's Disease
National Institutes of Health
CHDI Foundation
Harvard NeuroDiscovery Center
FWCI
1.29
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals